Poland· PL-100409370

Manti Extra

A famotidin, kombinationen product containing famotidinum + magnesii hydroxidum + calcii carbonas, registered in Poland by US Pharmacia Sp. z o.o.. The same ATC class is registered in 5 of our 19 countries.

ATC A02BA53

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedManti ExtraATCA02BA53REGISTER NO.PL-100409370PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Famotidin, kombinationen is registered in 5 of 19 countries.

Countries holding a registration under ATC A02BA53 (famotidin, kombinationen), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Famotidin, kombinationen · ATC A02BA53

5 / 19 countries

  • Canada
  • Finlandprice
  • Ireland
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Famotidinum + Magnesii hydroxidum + Calcii carbonas
Manufacturer
US Pharmacia Sp. z o.o.
Country
Poland (PL)
ATC code
A02BA53
ATC class
Famotidin, Kombinationen
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05903031289800
  • gtin
    05903031289794
  • gtin
    05904569252649

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Famotidin, kombinationen in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All famotidin, kombinationen products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • Bulgaria · Гастропротект
  • Finland · Pepcid Duo
  • Ireland · Pepcid Duo
  • Norway · Pepcidduo
  • Sweden · Pepcid Duo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/25c22ae6-a959-4ae5-98af-b9675b10a555
GET /v1/drugs/25c22ae6-a959-4ae5-98af-b9675b10a555?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki do rozgryzania i żucia",
  "source": "urpl",
  "strength": "10 mg + 165 mg + 800 mg",
  "packaging": "05903031289800 ¦ OTC ¦ 142353\n12 tabl.\n05903031289794 ¦ OTC ¦ 142354\n6 tabl.\n05904569252649 ¦ OTC ¦ 157480\n24 tabl.",
  "substance": "Famotidinum 10 mg + Magnesii hydroxidum 165 mg + Calcii carbonas 800 mg",
  "common_name": "Famotidinum + Magnesii hydroxidum + Calcii carbonas",
  "pl_product_id": "100409370",
  "pozwolenie_nr": "26706",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about famotidin, kombinationen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.